Search results
Results from the WOW.Com Content Network
As of 2023, the Indian pharmaceutical industry is the world's 13th largest by value and third largest in the world by volume. [8] The industry produces over 60,000 generic drugs in different 60 therapeutic categories. [8] India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7]
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease , cardiovascular disease , arthritis , diabetes , depression , paediatric and various other medical conditions. [ 3 ]
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
The U.S. drug regulator is set to increase the number of inspections at Indian drug manufacturing units in 2024 amid growing concerns over the quality of drugs, a top executive for the Food and ...
Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. . The company's drugs reach 70 countries [22] with a footprint that covers advanced markets such as USA, Europe, Japan, [23] Australia as well as emerging markets including India, the Philippines and South Africa to name a
IPA was founded in August 1999 by Dilip G Shah and six Indian drugmakers: Cipla, Dr. Reddy's, Lupin, Piramal, Ranbaxy, and Wockhardt. [1] IPA was founded to promote the cause of generic drugs in India [2] and has since expanded to include 24 domestic pharmaceutical companies. [3] Sudarshan Jain is the current secretary general of the IPA. [4]
On 7 April 2014, India-based Sun Pharmaceutical and Japan-based Daiichi Sankyo jointly announced the sale of the entire 63.4% share of Ranbaxy from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. [3]